Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

This study found that sodium zinc dihydrolipoylhistidinate reduced chemotherapy-induced hair loss in rats, suggesting its potential as a treatment for this side effect.

Tirzepatide may improve hair loss by reducing insulin resistance.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study used a zebrafish model and advanced mass spectrometry to identify 11 metabolites of epristeride, revealing significant effects on purine metabolism and aromatic amino acid biosynthesis, which may aid in developing anti-doping detection methods.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This study found that telogen effluvium occurred in two subjects taking 500 mg of mefloquine weekly, and gastrointestinal intolerance was observed at higher doses in additional acute studies.

Ritlecitinib works well and is safe for treating alopecia areata.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This abstract discusses the FitSpresso weight loss supplement's potential benefits and mechanisms but provides no clinical research findings; it reports on its ingredients and consumer ratings instead.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This study identified Azithromycin and Roxithromycin as novel senolytic antibiotics that effectively target and reduce senescent human fibroblast cells.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.